A Certificate of Analysis (COA) is the primary quality document that accompanies a batch of synthesized peptide. It records the analytical results for that specific lot — purity, identity, composition, and any additional assays the laboratory ran — so that researchers and quality-assurance staff can verify they received what was ordered and decide whether the material meets their requirements.
Reading a COA accurately requires a basic understanding of analytical chemistry and quality-assurance conventions. A number on a certificate is not self-interpreting: a "98% purity" claim means very different things depending on what assay generated it, whether the test was run by the manufacturer or an independent laboratory, and whether the certificate is genuinely tied to the batch in your hands.
This guide explains the structure of a typical peptide COA, the assays it should contain, how to interpret each one, and how to spot documentation that falls short of defensible quality standards. It is written as an educational and informational resource for researchers and informed readers. It is not medical advice, does not constitute an endorsement or recommendation to purchase or use any peptide, and does not address dosing or clinical application of any kind. For guidance on individual peptide pharmacology, consult primary literature and a qualified healthcare professional.
What a COA is — and what it isn't
A COA is a supplier-issued document attesting that a specific batch of material was tested and met stated specifications. At minimum it identifies the compound (name, molecular formula, molecular weight), the lot or batch number, the synthesis date or testing date, and the analytical results from one or more assays.
What a COA is not: it is not a certificate of identity by itself, it is not a safety evaluation, and it is not a clinical or research authorization. A COA only tells you about the specific tests run on the specific material — it says nothing about tests that were not run, and it cannot guarantee that the material is suitable for any particular use.
The most important single fact about any COA is who ran the tests. An in-house COA is prepared by the same organization that synthesized the material; the lab doing the analysis is not independent of the lab that made the product. A third-party COA is prepared by an analytical laboratory separate from the supplier/manufacturer, ideally accredited and traceable to the tested lot. The lab may still be paid by the supplier, so independence, accreditation, and batch traceability matter. Third-party testing creates a meaningful separation of incentives. This distinction appears nowhere in the numbers on the page; you have to look at the issuing organization listed on the document.
HPLC purity — what the percentage actually means
High-performance liquid chromatography (HPLC) is the standard method for measuring peptide purity. A sample is dissolved in solvent and pumped through a column; different components in the mixture separate based on their chemical affinity for the stationary phase. A UV detector (usually set at 220 nm, where the peptide bond absorbs) records each separated component as a peak on a chromatogram. The reported purity percentage is the area of the main peak divided by the total peak area — expressed as percent main-peak-area relative to all detected peaks.
Several nuances matter when you interpret this number. First, HPLC purity is a relative measure of what the detector can see under those specific conditions; it does not tell you the absolute mass of active peptide per unit weight. A sample could report 98% HPLC purity and still contain significant water, residual solvents, or counter-ions that the UV detector does not register. Second, detection wavelength matters: 220 nm detects peptide bonds broadly, while other wavelengths (254 nm, 280 nm) are selective for aromatic residues and will give different chromatograms for the same sample. Third, different column chemistries and gradient conditions can produce different apparent purities for the same material. Reputable suppliers report the column type, gradient conditions, and detection wavelength alongside the purity number.
Convention for research-grade peptides is typically 95% or 98% minimum HPLC purity by area. Clinical-grade material (used in regulated manufacturing) applies stricter standards and generally requires additional identity and impurity-profile tests. The chromatogram itself — not just the summary number — should ideally be available, since it lets you assess whether impurity peaks are small and clean or suggest a contaminated or degraded sample.
Mass spectrometry — confirming molecular identity
HPLC purity tells you how clean the main peak is relative to other peaks, but it cannot confirm that the main peak actually is the intended peptide. That confirmation requires mass spectrometry (MS).
Mass spec measures the mass-to-charge ratio (m/z) of ions in a sample. For peptides, the expected monoisotopic molecular weight can be calculated precisely from the amino acid sequence. The most common technique used for small-to-medium peptides is electrospray ionization (ESI-MS), which typically produces multiply-charged ions; the reported masses are the uncharged molecular weights calculated from those ions. Matrix-assisted laser desorption/ionization (MALDI-TOF) is also used and tends to produce singly-charged ions.
A COA should report the theoretical (expected) molecular weight alongside the observed molecular weight from the MS measurement. A match within acceptable tolerance — typically ±0.5 Da for most ESI-MS instruments on peptides under ~3 kDa, or ±1 Da at higher molecular weights — supports molecular identity by confirming the expected molecular mass. MS alone may not distinguish all isobaric substitutions, sequence variants, or modifications; higher-confidence identity may require MS/MS, sequencing, NMR, or orthogonal testing depending on the use case. A mismatch indicates the wrong compound, an incomplete synthesis, or a modification you were not told about.
For a credible research-grade peptide COA, MS identity confirmation should be treated as minimum expected documentation. A purity figure without an identity confirmation leaves open the possibility that you have a clean but wrong compound. Both tests together — HPLC purity + MS identity — form the minimum credible analytical package for a research-grade peptide COA.
Peptide content: net peptide vs gross weight
The purity percentage on a COA does not tell you how much of the material by weight is actually peptide. Lyophilized (freeze-dried) peptide powder is not pure peptide by mass: it also contains water (moisture absorbed from air or retained from lyophilization) and residual counter-ions, most commonly trifluoroacetate (TFA) or acetate, which associate with basic amino acid residues during synthesis and purification.
Net peptide content (also called peptide content by weight or true peptide content) is the percentage of the total weight that is actually the peptide molecule itself. A typical research-grade peptide might weigh out at what looks like 10 mg on a scale, but if net peptide content is 80%, then only 8 mg is actual peptide and 2 mg is water plus counter-ions. For experiments where molar concentration matters, using gross weight without knowing net peptide content introduces a systematic error.
Net peptide content is determined by nitrogen analysis (such as Kjeldahl or combustion elemental analysis) or, more commonly for routine QC, by quantitative amino acid analysis (AAA). Not every supplier includes this test. Where it is absent, the COA tells you purity relative to other UV-active compounds but not absolute peptide loading per gram. This matters most for experiments requiring precise stoichiometry — receptor binding assays, enzyme kinetics, cell-culture dose-response curves — and less for pilot screening work where approximate concentrations are acceptable.
Residual TFA is a specific concern worth noting separately: TFA is a potent inhibitor of some cell-based assays and has cytotoxic effects at higher concentrations. Suppliers that remove TFA by substitution with acetate or by treatment methods will note this on the COA or product specification. For cell culture work, TFA removal is generally recommended.
Water and counter-ion content
As an extension of net peptide content, well-characterized COAs may report water content and counter-ion (acetate or TFA) content separately. Water content is typically measured by Karl Fischer titration, a selective electrochemical method for water. Counter-ion content, when reported, is usually determined by ion chromatography.
Knowing these values allows a more complete accounting of what is in the vial. If water content is 5% and TFA content is 12%, then net peptide content is approximately 83% — meaning the supplier is reporting three separate components that together explain the non-peptide fraction of the total weight.
In practice, many research-grade suppliers report only HPLC purity and molecular weight. Counter-ion content and water content are reported more often by pharmaceutical-grade suppliers or by academic reference-standard programs (such as those run by USP or NIST). Seeing these values is a sign of a more thorough analytical program; their absence doesn't necessarily indicate a problem, but their presence is a positive indicator of documentation maturity.
Sterility and endotoxin testing — when they apply
Sterility testing (per pharmacopeial methods such as USP <71>) and bacterial endotoxin testing (BET, per USP <85> or equivalent) are standard requirements for materials intended for parenteral (injectable) clinical use. For research-grade peptides sold as laboratory chemicals, these tests are not required and are often not performed.
Endotoxins are lipopolysaccharide fragments from the outer membrane of gram-negative bacteria. They are potent inducers of inflammation and fever, and they can confound in-vitro cell-culture results at concentrations well below those that cause obvious turbidity or odor changes in solution. The limulus amebocyte lysate (LAL) assay is the standard method for endotoxin detection; a recombinant factor C (rFC) assay is an alternative that avoids using horseshoe crab hemolymph.
For research applications involving cell culture — especially primary cell culture, cytokine assays, or any work where inflammation is a measured endpoint — endotoxin testing matters. A COA that includes LAL or rFC results, with a reported endotoxin level in EU/mg, provides meaningful quality information for those use cases. For mass-spectrometry reference standards, NMR experiments, or structural studies, endotoxin is typically irrelevant.
Sterility testing (ensuring no viable microorganisms) is a different, slower assay (typically 14 days of incubation) and is rarely performed on non-clinical research peptides. It becomes relevant when material is being prepared for IND-enabling studies or regulated clinical investigation under formal regulatory oversight — well outside the scope of what a standard research supplier offers.
Verifying a COA — batch matching and third-party confirmation
A COA has no value if it describes a different batch of material than the one you received. Batch matching is the process of confirming that the lot number on the COA matches the lot number on the container label. This sounds obvious but is a common source of error when documentation is loosely handled.
Beyond batch matching, there are three additional verification checks that strengthen confidence in a COA's authenticity:
**Date plausibility.** The test date on the COA should plausibly precede the shipment date. A COA dated after the product arrived is either a documentation error or a sign that the certificate was prepared post-hoc to match an order rather than to document actual testing.
**Issuing laboratory identity.** The COA should clearly identify the laboratory that ran the tests, ideally with contact information, accreditation number (ISO/IEC 17025 is the standard for analytical testing laboratories), and a named signatory. A COA that names only the supplier as the testing entity is an in-house certificate. This is not automatically fraudulent, but it carries less evidentiary weight than a certificate from an accredited independent laboratory.
**Consistency between the chromatogram and the reported number.** If a chromatogram is provided alongside the purity percentage, the two should agree. A small impurity peak in a chromatogram that is reported as 99.5% pure should look proportionally very small. If the visual impression of the chromatogram does not match the claimed purity, something is wrong.
Some suppliers now provide QR codes or batch-specific URLs that link directly to stored analytical data — a practice that substantially reduces the possibility of documentation reuse across batches. Where this feature is available, using it is straightforward.
References and analytical standards
The claims in this guide are grounded in established analytical-chemistry standards and pharmacopeial methods. Key references:
**HPLC area-percent purity.** Reported as UV area-percent at the stated detector wavelength (typically 220 nm for peptide bonds; 254 nm or 280 nm for aromatic-residue selectivity). Area-percent purity is a relative measure and does not reflect non-UV-active components (water, counter-ions, residual solvents).
**Research-grade purity conventions.** Thresholds of ≥95% and ≥98% HPLC area-percent are widely used conventions in the peptide research community; they are not regulatory requirements for research chemicals but represent common specification tiers cited in supplier documentation and method-development literature.
**MS mass tolerance.** Accepted tolerances of ±0.5 Da (ESI-MS, <~3 kDa) and ±1 Da (higher molecular weights) reflect standard instrument calibration practice for peptide identity confirmation by intact-mass measurement.
**Net peptide content methods.** Quantitative amino acid analysis (AAA) and nitrogen-based methods including Kjeldahl digestion and combustion (Dumas) elemental analysis are the established approaches for determining true peptide mass fraction. These methods are referenced in ICH guidelines (e.g., ICH Q6A) and standard analytical chemistry practice.
**TFA effects in cell culture.** Trifluoroacetate residues from HPLC purification are documented to cause assay interference and cytotoxicity in cell-based work; this is a recognized consideration in peptide QC literature and is addressed in supplier technical notes and published cell-biology method guidance.
**USP <71> Sterility Tests.** The pharmacopeial reference for sterility testing of injectable and ophthalmic preparations (United States Pharmacopeia, General Chapter <71>).
**USP <85> Bacterial Endotoxins Test.** The pharmacopeial reference for the limulus amebocyte lysate (LAL) and recombinant factor C (rFC) endotoxin assays (United States Pharmacopeia, General Chapter <85>).
**Karl Fischer titration.** The selective electrochemical method for water determination referenced throughout analytical chemistry; documented in USP <921> Water Determination and equivalent pharmacopeial chapters.
**Ion chromatography for counter-ions.** Standard method for quantifying residual acetate and trifluoroacetate in peptide drug substances; referenced in pharmaceutical analytical chemistry practice and ICH guidelines.
General handling, storage, and reconstitution principles
These are general laboratory QA principles only and are not instructions for preparing peptides for human or animal administration.
The analytical results on a COA describe the material at the time it was tested. Those results can change if the material is stored or handled improperly afterward. The following are standard laboratory principles for maintaining peptide integrity; they are not instructions for any specific application.
**Lyophilized vs reconstituted stability.** Lyophilized (freeze-dried) peptides are considerably more stable than peptides in solution. Water molecules in a reconstituted solution facilitate hydrolysis and oxidation of the peptide backbone and sensitive residues. Common laboratory practice is to keep peptides in lyophilized form until the point of use and to avoid reconstitution until needed.
**Temperature.** Many peptide handling references recommend storage of lyophilized peptides at −20 °C for long-term stability. Short-term (weeks) storage at 2–8 °C is acceptable for many compounds. Room temperature storage is generally discouraged for extended periods. Reconstituted peptide solutions are commonly refrigerated and used promptly; for longer-term storage they are typically aliquoted and frozen at −80 °C to minimize freeze-thaw cycles.
**Light exposure.** Peptides containing tyrosine, tryptophan, phenylalanine, or cysteine residues are susceptible to photodegradation. Amber vials and foil-wrapped containers protect against UV exposure. If your application involves a peptide with these residues, minimize exposure to direct light.
**Reconstitution solvents.** The appropriate reconstitution solvent depends on the peptide's sequence and the downstream use. Water (HPLC-grade or equivalent), dilute acetic acid, DMSO, and phosphate-buffered saline are commonly used. Using a solvent incompatible with the peptide's solubility characteristics can result in a cloudy solution or incomplete reconstitution — meaning not all the mass in the vial is actually in solution. A COA or technical data sheet should indicate recommended solvents.
**Container integrity.** Reseal vials promptly after use. Moisture ingress degrades lyophilized peptides over time. Some suppliers use nitrogen purge or vacuum seal under inert gas; if the seal is broken on arrival, this should be noted and the supplier contacted.
Frequently asked questions
Convention in the research community is ≥95% main-peak area by HPLC for general research purposes, and ≥98% for applications requiring higher precision — quantitative binding assays, reference standards, or highly controlled dose-response experiments. These are conventional thresholds, not regulatory requirements for research chemicals. The appropriate specification depends on the sensitivity of your application to minor impurities.
Yes, both are possible. A common fraud pattern is submitting one batch to a third-party laboratory, obtaining a clean certificate, then shipping a different batch with the same documentation. Protections against this include: reviewing documentation from sources that provide batch-specific testing traceable by lot number, prioritizing sources with QR-coded or URL-linked batch records, requesting the raw chromatogram data rather than just the summary, and — for critical applications — sending a portion of the received material to an independent laboratory for verification testing.
HPLC purity measures the fraction of UV-detectable signal attributed to the main peak, relative to all detected peaks. It does not account for water, residual solvents, or counter-ions that don't produce a UV signal. Net peptide content (also called peptide content by weight) measures the fraction of the total dry weight that is actually peptide molecule, determined by nitrogen analysis or amino acid analysis. A compound can show 99% HPLC purity and only 75–85% net peptide content if it carries significant water and counter-ion loading.
Trifluoroacetate (TFA) is used in HPLC purification and residually ion-pairs with basic amino acid residues (Arg, Lys, His) in the final product. At low concentrations it may be benign for most applications; at higher concentrations or for cell culture work, TFA can inhibit assays and show cytotoxic effects. Whether TFA has been removed (by counter-ion exchange or other methods) should be stated on the COA or product specification. When in doubt, request confirmation from the supplier and consider whether your application requires TFA-free material.
Endotoxin testing matters whenever your research involves cell-based assays where an inflammatory response could confound results — primary cells, cytokine measurements, macrophage assays, or any protocol where the readout is sensitive to LPS-like contamination. Sterility testing (live organism absence) is relevant mainly when material is being prepared under GMP conditions for IND-enabling studies or regulated clinical investigation. Most research peptides do not carry these certifications; if your work requires them, it typically means engaging a GMP contract manufacturer, not a standard research-chemical supplier.
Stop. A lot number mismatch means the certificate you have describes different material than what is in the container. Contact the supplier immediately and request the correct COA for your specific lot. Do not proceed with your experiment using a mismatched certificate. If the supplier cannot provide a matching certificate, the material's quality is uncharacterized and it should not be used in any context where quality documentation is required.